Health Impact Study of Aquatabs in Tamale, Ghana

October 29, 2007 updated by: Centers for Disease Control and Prevention

Health Impact Study of a Water Treatment Tablet, Aquatabs, in Tamale, Ghana

The purpose of this study to determine whether Aquatabs, a water treatment tablet, reduces diarrheal diseases in a peri-urban population of Tamale, Ghana.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

240

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Tamale, Ghana
        • NewEnergy
      • Tamale, Ghana
        • University of Development Studies
    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Emory University Center for Global Safe Water

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Households with at least one child under 5 years old

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: A
Placebo group does not receive Aquatabs.
Placebo
Experimental: B
Intervention arms receives Aquatabs.
Intervention arm receives NaDCC tablets to use for to disinfect their household water for use for 20L of water. Ideally, disinfection occurs every day.
Other Names:
  • Aquatabs

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Measure the impact of Aquatabs on diarrhea among persons in households in Tamale, Ghana.
Time Frame: 12 weeks
12 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Assess the microbiological quality of household water among persons living in Tamale, Ghana.
Time Frame: 12 weeks
12 weeks
Determine the acceptability of Aquatabs.
Time Frame: 12 weeks
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Seema Jain, MD, Centers for Disease Control and Prevention
  • Principal Investigator: Robert Quick, MD, Centers for Disease Control and Prevention

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2006

Study Completion (Actual)

November 1, 2006

Study Registration Dates

First Submitted

November 10, 2005

First Submitted That Met QC Criteria

November 10, 2005

First Posted (Estimate)

November 15, 2005

Study Record Updates

Last Update Posted (Estimate)

October 30, 2007

Last Update Submitted That Met QC Criteria

October 29, 2007

Last Verified

October 1, 2007

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diarrhea

Clinical Trials on Placebo

Subscribe